NCT04998396View on ClinicalTrials.gov

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

October 13, 2026

Study Completion Date

October 8, 2030

Conditions
Canavan Disease
Interventions
BIOLOGICAL

AAV9 BBP-812

Sterile solution for injection for 1-time use via volumetric infusion pump

Trial Locations (4)

10065

COMPLETED

Weill Cornell Medicine; Division of Pediatric Neurology, New York

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

94609

RECRUITING

UCSF Benioff Children's Hospital Oakland, Oakland

02114

RECRUITING

Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND), Boston

Sponsors

Lead Sponsor

Aspa Therapeutics
All Listed Sponsors
lead

Aspa Therapeutics

INDUSTRY

NCT04998396 - A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial) | Biotech Hunter | Biotech Hunter